Quercetin and cancer chemoprevention. by Gibellini, Lara et al.
UCLA
UCLA Previously Published Works
Title
Quercetin and cancer chemoprevention.
Permalink
https://escholarship.org/uc/item/8023b10j
Authors
Gibellini, Lara
Pinti, Marcello
Nasi, Milena
et al.
Publication Date
2011
DOI
10.1093/ecam/neq053
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2011, Article ID 591356, 15 pages
doi:10.1093/ecam/neq053
Review Article
Quercetin and Cancer Chemoprevention
Lara Gibellini,1 Marcello Pinti,1 Milena Nasi,1 Jonas P. Montagna,1 Sara De Biasi,1
Erika Roat,1 Linda Bertoncelli,1 Edwin L. Cooper,2 and Andrea Cossarizza1
1Department of Biomedical Sciences, University of Modena and Reggio Emilia School of Medicine, 41125 Modena, Italy
2David Geffen School of Medicine, UCLA Medical Center (CHS), Los Angeles, CA, USA
Correspondence should be addressed to Andrea Cossarizza, andrea.cossarizza@unimore.it
Received 24 November 2009; Accepted 9 April 2010
Copyright © 2011 Lara Gibellini et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Several molecules present in the diet, including flavonoids, can inhibit the growth of cancer cells with an ability to act as
“chemopreventers”. Their cancer-preventive effects have been attributed to various mechanisms, including the induction of cell-
cycle arrest and/or apoptosis as well as the antioxidant functions. The antioxidant activity of chemopreventers has recently
received a great interest, essentially because oxidative stress participates in the initiation and progression of different pathological
conditions, including cancer. Since antioxidants are capable of preventing oxidative damage, the wide use of natural food-derived
antioxidants is receiving greater attention as potential anti-carcinogens. Among flavonoids, quercetin (Qu) is considered an
excellent free-radical scavenging antioxidant, even if such an activity strongly depends on the intracellular availability of reduced
glutathione. Apart from antioxidant activity, Qu also exerts a direct, pro-apoptotic effect in tumor cells, and can indeed block the
growth of several human cancer cell lines at different phases of the cell cycle. Both these effects have been documented in a wide
variety of cellular models as well as in animal models. The high toxicity exerted by Qu on cancer cells perfectly matches with the
almost total absence of any damages for normal, non-transformed cells. In this review we discuss the molecular mechanisms that
are based on the biological effects of Qu, and their relevance for human health.
1. Introduction
1.1. Chemoprevention and Diet. The field of cancer chemo-
prevention, defined as the long-term intervention with
natural or synthetic molecules to prevent, inhibit or reverse
carcinogenesis, is gaining increasing importance, especially
at a time when the use of complementary and alternative
medicine (CAM) and natural health products is consistently
increasing [1]. At present, the use of CAM in oncology
represents a challenging area of interest since remarkable
scientific evidences suggest that natural dietary factors can
inhibit the process of carcinogenesis and can effectively
influence the risk of cancer in humans. The idea of cancer
chemoprevention arises from both statistical and epidemi-
ological data showing that a modification of the lifestyle is
associated with lower incidence of certain types of cancers
(i.e., colorectal, stomach, lung and esophageal cancers) and
that, in particular, such modifications include a vegetable-
and fruit-rich diet [2].
Accumulating evidences from observational and
prospective studies indicate that dietary components may
substantially alter the natural history of carcinogenesis, and
that an inverse correlation between a high consumption
of fruits and vegetables and the incidence of some cancers
does exist [3, 4]. Indeed, a high consumption of fruits
and vegetables was associated with a reduced risk of
intestinal cancer, especially of colon cancer, in former
smokers or in no-smokers, whereas no preventive effect
was found in current smokers [5]. Consumption of
fruits, particularly citrus fruit, as well as vegetables, likely
correlates with decreased esophageal cancer risk [6, 7].
Green leafy vegetables, rather than fruit, might also have
a protective effect against lung cancer [8, 9]. High intake
of cruciferous vegetables may be associated with reduced
risk of aggressive prostate cancer [10]. With regard to
renal cancer, although the results of case-control studies
are not fully consistent and often contradictory, analyses
performed on very large number of patients have found
an inverse association for the intake of total fruit [11],
total vegetables [12], and some subgroups of vegetables
such as cruciferous vegetables, dark green vegetables and
yellow-orange vegetables [13]. Conversely, positive effects of
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fruit and vegetable consumption, combined or separately,
were not found as far as the risk of developing bladder or
ovary cancer was concerned [14].
1.2. Natural Chemopreventers. The majority of the case-
control studies focused on the use of fruits and vegeta-
bles because these items, which include soybean, ginger,
onion, cabbage, cauliflower, turmeric, are the basis of
most diets throughout the world, and represent important
sources of potentially non-toxic molecules (dietary phyto-
chemicals). These molecules can exert a cancer-preventive
effect and therefore are termed as “chemopreventers” [15].
Among them, the most studied are curcumin, quercetin
(Qu), resveratrol, luteolin, genistein, (−)-epigallocatechin-
3-gallate (EGCG), lycopene and, in general, flavonoids and
polyphenols [16–19]. A majority of studies have analyzed
the biological properties (e.g., antioxidant, antimicrobial,
antiproliferative, pro- or anti-apoptotic) of the aforemen-
tioned molecules that are present, along with other com-
pounds, in aqueous extracts from plants [20–25].
A relevant interest is present on the mechanism(s)
of action of chemopreventers, especially concerning the
identification of molecular and cellular targets of CAM com-
pounds, and the molecular basis of their cancer-preventive
action. At the biochemical level, chemopreventers usually
act as modulators of signal transduction pathways that are
involved in almost all biological processes: cell prolifera-
tion, apoptosis, cell migration, cell differentiation, oxidative
balance and inflammation [26–29]. Chemopreventers often
have preferentially an antioxidant activity; however, they are
also able to exert anti-proliferation and anti-inflammation
actions. Indeed, they can directly modulate several proteins
that are involved in cell cycle and cellular homeostasis
and whose deregulation can play a role in carcinogenesis,
such as p53, p73, p21, Bax, Bcl-2, COX-2, NF-kB, catalase,
glutathione (GSH)-peroxidase [4, 30, 31]. The antioxidant
activity of chemopreventers is nowadays gaining more
importance because of the observations, both in vitro and in
vivo, that the deregulation of free-radical homeostasis can be
involved in carcinogenesis [32].
2. Carcinogenesis and Reactive Oxygen Species
2.1. Reactive Oxygen Species Induced Carcinogenesis in Ani-
mal Models. The evidence of a strong association between
the production of free radicals and carcinogenesis mainly
derives from in vitro studies showing that some pro-oxidant
chemicals promote tumors in several animalmodels, whereas
primary endogenous antioxidant enzymes could interfere
with tumor promotion. For instance, 1,2-dimethylhydrazine
induces colon carcinogenesis in rats [33, 34], whereas
benzoylperoxide promotes papillomas and carcinomas after
7,12-dimethylbenz[a]anthracene initiation in mice [35]. In
rat liver epithelial cells treated with N-methyl-N ′-nitro-
N-nitrosoguanidine, hydrogen peroxide exerts a tumor
promoting activity [36]. Conversely, the overexpression of
manganese superoxide dismutase (MnSOD) reduces tumor
incidence in a multistage skin carcinogenesis mouse model
[37]. A combined deficiency in two mitochondrial-localized
antioxidant enzymes, MnSOD and GSH peroxidase-1 (Gpx-
1), determines an increased incidence of neoplasms in mice
[38].
2.2. Reactive Oxygen Species Induced Carcinogenesis in Human
Cells. The involvement of reactive oxygen species (ROS) in
tumor progression has also been demonstrated in human
cells. NADPH oxidase 1 (Nox1), an enzyme that produces
superoxide (which is in turn dismuted to hydrogen perox-
ide), is overexpressed in colon and prostate cancer cell lines
[39, 40], while its downregulation reverses tumor growth
[41]. Decreased levels of MnSOD and rapid cell doubling
time have been reported in human pancreatic cancer cell
lines at various levels of differentiation [42].
These studies are consistent with the observation that
a significant shift of cellular oxidative balance could lead
to tumor promotion or progression, as ROS are involved
in damaging of DNA as well as in mitogenic signaling
[43–45]. Endogenous ROS are generally supposed to cause
DNA damage [46], through the production of oxidized
bases and DNA strand breaks, and to be a relevant factor
contributing to chromosome instability and accumulation
of mutations and deletions, finally leading to cancer [47].
About 1% of oxygen consumption results in the production
of ROS [46], thus implying that, in every cell, ROS can
damage ∼20 000 DNA bases per day [48]. Cells have evolved
several antioxidant defenses, including repair and detoxifying
enzymes, and small scavenger molecules, such as GSH.
Nevertheless, the presence of these intracellular protective
systems is not sufficient to ensure an adequate and complete
removal of oxidative damages.
Apart from the direct action on DNA, it has to be
noted that ROS act as secondary messengers in several
pathways, which can potentially promote carcinogenic pro-
cesses, including resistance to apoptosis, increase in cell
proliferation and production of metastasis [32]. Indeed, ROS
have been involved in the transcriptional activation of several
proto-oncogenes, such as c-FOS, c-JUN and c-MYC. In
human hepatoma cells, ROS modulate the expression of c-
FOS and c-JUN through PKB pathway [49]. Furthermore,
p66Shc, which is involved in the regulation of ROS signaling,
is responsible for androgenic proliferation signals through
ROS production in prostate cancer cells that are positive
to androgen receptor [50]. Finally, in anaplastic large cell
lymphomas, the use of nordihydroguaiaretic acid, which is
an inhibitor of lipoxygenase, results in the inhibition of
several pathways which are involved in antiapoptotic and
pro-mitogenic functions [51].
3. Flavonoids and Their Possible Role in
Cancer Chemoprevention
3.1. Flavonoids in the Diet. Among chemopreventers, one
of the most studied group of antioxidant compounds are
flavonoids. Flavonoids are a large heterogeneous group of
benzo-γ-pyrone derivatives that share a common carbon
skeleton of dyphenylpropanes [52] and can be divided into
six different classes, namely flavonols, flavones, flavanones,
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flavanols, isoflavones and anthocyanidins, according to their
molecular structure [53].
Flavonoids are largely present in fruits, vegetables, aro-
matic plants, medical herbs, tea and red wine [54]. It is
extremely difficult to estimate the daily human intake of
flavonoids, especially because of the lack of standardized
analytical methods [55]. However, the average daily intake
of the most abundant flavonoids, catechins, is ∼100mg
[56]. Similar to daily intake, it is also quite complex to
assess and quantify the bioavailability of flavonoids [57].
Nevertheless, metabolized forms of flavonoids present in
blood significantly differ from the native compounds, and
plasma concentration of total metabolites can have a range
0–4 μmol L−1 with an intake of 50 mg of aglycone, which is
the non-sugar compound left after partial metabolization of
the original flavonoid [58].
3.2. Cancer Chemoprevention by Flavonoids: Molecular
Mechanisms. Results from cell culture and animal models
reveal that flavonoids exert positive preventive effects in
carcinogenesis and neurodegenerative disorders essentially
because of their antioxidant activity, their capacity to
affect the expression of several detoxifying enzymes [59],
and their ability to modulate protein signaling cascades
[60]. Flavonoids can interfere with specific stages of the
carcinogenic process, and can inhibit cell proliferation and
induce apoptosis in several types of cancer cells.
EGCG is one of the most intensively studied flavonoids
as it is the major polyphenolic component of green tea.
EGCG inhibits cell proliferation and induces apoptosis in
several human tumor cell lines, including CaSki and HeLa
cervical cells [61], Hep-2 cells [62], laryngeal squamous
carcinoma cells [63], SW780 and TCCSUP bladder urothelial
cells [64], melanoma cells [65], adrenal NCI-H295 cancer
cells [66] and A549 lung cancer cells [67]. The mechanisms
by which apoptosis is triggered differ depending on the cell
line and include via death receptor, or via mitochondrial and
endoplasmic reticulum-dependent pathways.
The cancer-preventive properties of flavonoids can be
attributed to their capacity of quenching ROS, reactive nitro-
gen species (RNS) and other radicals. Tea catechins, espe-
cially EGCG, react with superoxide radical, hydroxyl radical,
peroxyl radical and peroxynitrite [68]. Resveratrol, present
in red wine, grapes and peanuts, is a scavenger of superoxide
and peroxynitrite radicals [69], and genistein, mainly derived
from soy, can scavenge exogenous or endogenous hydrogen
peroxide in cell models [70]. Moreover, flavonoids exert their
protective antioxidant effect not only by quenching ROS,
but also by modulating the activity of several detoxifying
enzymes, including lipoxygenase, cycloxygenase, inducible
nitric oxide synthase, monoxygenase, xanthine oxidase and
NADH oxidase [71–75]. Among enzymes that are inhibited
by flavonoids, thioredoxin reductases have to be quoted,
as they are involved in cellular redox control, and are
overexpressed in different aggressive tumors [76].
Growing evidences suggest that flavonoids (in particular,
resveratrol and quercetin) may contribute to chromatin
remodeling and thus interfere with epigenetic alterations that
are important in cancer progression. Chromatin is remod-
eled by chemical modifications of DNA and histones, such as
DNA methylation and multiple histone modifications, such
as methylation, phosphorylation, acetylation, sumoylation
and ubiquitination; for example, resveratrol activates sirtuin
(SIRT)-1, a member of histone deacetylase (HDAC) family,
which plays key roles in cell survival and apoptosis [77]. The
network of SIRT1-modulated signals is wide and complex,
and involves SIRT1 direct interactions with several proteins
involved in cell survival (p53, bax, E2F1, FOXO3, Dif1), DNA
repair (WRN, Ku70, RAD51) and cell cycle/apoptosis (β-
catenin, survivin, NFκB) [78]. The activation of SIRT1 by
resveratrol induces the formation of SIRT1-p300 complexes,
causing the inactivation of p300 acetyltransferase and a
reduction in the acetylation of both β-catenin and NFκB-
p65. The main consequence of this phenomenon is the
downregulation of the multidrug resistance (MDR)-1 and
Bcl-xL genes with the subsequent stimulation of cell death,
as well as the reduction of chemoresistance in breast tumor
cells [79].
Several catechol-containing dietary polyphenols are
capable of modulating DNA methylation. Among them,
EGCG is a potent and efficacious in vitro inhibitor of DNA
methyltransferase (DNMT)-1, whereas Qu can demethylate
the p16INK4a gene promoter, whose hypermethylation is
present in human colon cancer cells [80]. Qu also activates
histone deacetylase enzymatic activity, thus reducing the
acetylation of histone H3 in human prostate cancer cells. The
deacetylation of H3 could be responsible for the inhibition of
survivin expression, and for the subsequent sensitization to
TRAIL-induced apoptosis [81].
3.3. Cancer Chemoprevention by Flavonoids in Human.
Regarding flavonoids as chemopreventers in humans, con-
trasting results have been reported, and indeed some studies
showed an inverse correlation between the intake of total
dietary flavonoids and the risk of cancer [82–85], whereas
others did not evidence any association [86]. Furthermore,
the importance of risk factors such as smoke has to be
taken into account, since in different groups of patients,
a limited evidence for a preventive effect of flavonoids on
the development of pancreatic cancer has been reported.
For example, no association between flavonoid intake and
pancreatic cancer risk was found in male current smokers
[87]. The Multiethnic Cohort Study, on the contrary,
reported that the intake of total flavonols was associated with
a reduced pancreatic cancer risk among current smokers,
but not in never or former smokers [88]. Lack of pre-
ventive effect was described in the case of ovarian can-
cer [89]. Conversely, several other epidemiological studies
confirmed the protective role of a high flavonoid intake
against colorectal [90, 91] and lung cancers [92]. Interest-
ingly, although natural chemopreventers have undergone
extensive mechanistic investigation at the molecular and
cellular level, their preclinical efficacy needs to be further
explored, and clinical trials have only recently started to
investigate the potential preventive role of these compounds
[93].
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4. Qu and Its Molecular Role in
Cancer Chemoprevention
4.1. The Importance of the Diet. Qu (3,3′,4′,5,7-penta-
hydroxyflavone) is an important dietary flavonoid, present
in different vegetables, fruits, seeds, nuts, tea and red wine
[94–96]. The average daily intake of Qu can reach 30mg in
most Western countries [97], and its bioavailability depends
on the metabolic form present in the food. Indeed, Qu
obtained from plant source is in the form of Qu-glucose
conjugates (Qu glucosides), which are absorbed in the
apical membrane of the enterocytes. Once absorbed, Qu
glucosides are hydrolyzed to generate Qu aglycone which is
further metabolized to the methylated, sulfonylated and glu-
curonidated forms by the enterocytic transferases [98]. Qu
metabolites are then transported first to the intestinal lumen
[98], and then to the liver, where other conjugation reactions
take place to form Qu-3-glucuronide and Qu-3′-sulfate,
which are the major Qu-derived circulating compounds in
human plasma [99, 100]. According to recent studies on
Qu bioavailability [58], when Qu is absorbed in the form
of Qu glucosides, the peak plasma concentration ranges
from 3.5 to 5.0 μmol L−1. In the unconjugated form, Qu
absorption is less efficient, and peak plasma concentration
is <0.33 μmol L−1.
The study of Qu as potential chemopreventer is assuming
increasing importance considering its involvement in the
suppression of many tumor-related processes including
oxidative stress, apoptosis, proliferation and metastasis. Qu
has also received greater attention as pro-apoptotic flavonoid
with a specific and almost exclusive activity on tumor cell
lines rather than normal, non-transformed cells [101].
4.2. Two Faces of the Same Molecule: Anti-Oxidant and
Pro-Oxidant Properties. Qu is considered an excellent free-
radical scavenging antioxidant owing to the high number
of hydroxyl groups and conjugated π orbitals by which
Qu can donate electrons or hydrogen, and scavenge H2O2
and superoxide anion (•O2−) [102]. The reaction of Qu
with •O2− leads to the generation of the semiquinone
radical and H2O2 [103]. Qu also reacts with H2O2 in the
presence of peroxidases, and thus it decreases H2O2 levels
and protects cells against H2O2 damage; nevertheless, during
the same process potentially harmful reactive oxidation
products are also formed. The first oxidation product of Qu
is a semiquinone radical [103]. This radical is unstable and
rapidly undergoes a second oxidation reaction that produces
another quinone (Qu-quinone, QQ) [103]. Since QQ can
react with proteins, lipids and DNA, it is responsible for
protein and DNA damage as well as lipid peroxidation. As
far as DNA is concerned, QQ canmediate DNA strand breaks
and can induce the oxidation of 2′-deoxyguanosine to form
8-hydroxy-2′-deoxyguanosine [104].
Biochemically, QQ is highly reactive towards thiols and
preferentially reacts with reduced GSH to form relatively
stable GSH-oxidized Qu, that is, 6-glutathionyl-Qu (GSQ)
and 8-GSQ [105]. Along with 6-GSQ and 8-GSQ, the
generation of 2′-GSQ has also been characterized in dermal
fibroblasts [106]. The reaction leading to the formation
of GSQ is reversible and glutathionyl-Qu adducts can be
continuously dissociated intoQQ andGSH [107]. As a result,
in the presence of high GSH concentrations, oxidized Qu
reacts with GSH to form GSQ again, and the reversibility
of the reaction ensures the protection against QQ toxicity.
In the presence of low GSH content, oxidized Qu reacts
with protein thiols, exerting a toxic effect within cells
[107, 108]. Similarly, long exposure to Qu along with high
Qu concentration, causes a reduction in GSH content,
suggesting the inability of Qu to cope with ROS for that
period. As a consequence, the pro-oxidant effect of Qu
could prevail over the antioxidant effect and result in cell
death by damaging cellular compartments [109, 110]. As
shown in Figure 1, when high levels of GSH are present, Qu-
derived semiquinone and quinoidal products are constantly
reduced, thus limiting Qu cytotoxicity and enabling Qu
to act as antioxidant rather than as pro-oxidant [111].
The antioxidant capability of Qu strongly depends on the
intracellular availability of GSH, since, in Qu-treated cells,
alterations typical of apoptosis appear when intracellular
GSH is completely depleted. Indeed, in different cellular
models low concentrations of Qu induce cell proliferation
and increase the antioxidant capacity of the cells, whereas
higher concentrations of Qu decrease antioxidant capacity
and thiol content, ultimately causing cell death [112].
4.3. Cell Cycle as a Possible Target. Apart from scavenging
ROS, another important effect of Qu is to regulate cell
cycle by modulating several molecular targets, including p21,
cyclin B, p27, cyclin-dependent kinases and topoisomerase
II, even if the mechanisms involved have not been elucidated
yet. Depending on the cell type and tumor origin, Qu
is able to block the cell cycle at G2/M or at the G1/S
transition (Figure 2). In particular, Qu causes G2/M arrest
in human esophageal squamous cell carcinoma cell line
through up-regulation of p73 and p21waf1 and subsequent
down-regulation of cyclin B1, both at the mRNA and protein
levels [113]. In human breast carcinoma cell lines such as SK-
Br3, MDA-MB-453 andMDA-MB-231 cells, low doses of Qu
inhibit proliferation. Cell-cycle arrest occurs at the G1 phase
through the induction of p21 and through the concomitant
decrease of phosphorylation of the retinoblastoma protein
(pRb). In the same cell model, Qu downregulates the
cyclin B1 and cyclin-dependent kinase (CDK) 1, which
are essential in the progression to the G2/M phases of
the cell cycle [114]. Similarly, in the human lung cancer
cells NCI-H209, Qu glucuronides induce cell-cycle arrest at
G2/M phase by increasing the expressions of proteins such
as cyclin B, Cdc25c-ser-216-p and Wee1 [115]. A similar
antiproliferative effect has also been observed both for highly
or moderately aggressive prostate cancer cell lines, whereas
no effect has been found for poorly aggressive prostate cancer
cells [116]. In HepG2 human hepatoma cells, Qu blocks
cell-cycle progression at the G1 phase, and exerts this effect
through the increase of p21 and p27 and p53 [117]. Similar
effects on the cell cycle have also been reported in SW872
cells [112].
Topoisomerase II (TopoII) is another potential and
delicate target of Qu [118, 119]. Of note, the ability of
Evidence-Based Complementary and Alternative Medicine 5
Quercetin (Qu)
Qu-quinone
(QQ)
High GSH
DNA and protein
damages
Oxidative
stress
Low GSH
Glutathionyl
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Figure 1: Antioxidant and pro-oxidant effects of Qu in the presence
of low and high levels of reduced GSH. The antioxidant and
pro-oxidant effects of Qu strongly depend upon the availability
of intracellular reduced GSH. During an oxidative stress, in
the presence of peroxidases, Qu reacts with H2O2 to form a
semiquinone radical that is rapidly oxidized to QQ. QQ has a
pro-oxidant effect; its high reactivity towards protein thiols and
DNA leads to cell damage and cytotoxicity. QQ is also highly
reactive towards thiols, and preferentially reacts with GSH to form
relatively stable protein-oxidized Qu adducts such as 6-GSQ and
8-GSQ. The reversibility of this reaction allows the continuous
dissociation of GSQ into GSH and QQ. In the presence of high GSH
concentrations, QQ reacts with GSH to form GSQ again, and QQ
cannot exert its cytotoxic effects, whereas when low levels of GSH
are present, QQ reacts with protein thiols, thus leading to cellular
damage.
Qu to directly poison TopoII through the stabilization of
double strand breaks in the TopoII-DNA cleavage complexes
could account for genetic rearrangements leading primary
hematopoietic progenitor cells to develop mixed-lineage
leukemia [120].
4.4. Direct Pro-Apoptotic Effects of Qu. Collectively, the pro-
apoptotic effects of Qu may result from multiple pathways.
First, in MDA-MB-231 cells, Qu treatment increases cytoso-
lic Ca2+ levels and reduces the mitochondrial membrane
potential (MMP), thus promoting activation of caspase-3,
-8 and -9 [26]. The capability of Qu to induce apoptosis
via mitochondrial pathway has been confirmed in U937 cell
line [109, 121]. In these cells, Qu disrupts MMP [109, 121],
which in turn provokes the release of cytochrome c in
the cytoplasm [122], and subsequently activates multiple
caspases, such as caspase-3 and -7 [123]. Second, Qu
inhibits cell growth and apoptosis by down-regulating the
transcriptional activity of β-catenin/Tcf signaling, with the
consequent down-regulation of cyclin D1 and survivin [124,
125]. The Qu-induced regulation of apoptosis through the
modulation of survivin has been demonstrated to have a
controversial fashion in glioma cells as well as in lung
carcinoma cell lines [126, 127]. Thus, while in glioma cells
S
G2M
G1
CDK1
Cyclin B
G1/S checkpoint
G2/M checkpoint
p53
p27
CDK2
Cyclin A
CDK2
Cyclin E
CDK4/6
Cyclin D
Caspases Apoptosis
Qu
Qu
Qu
MMP collapse
p21
p21
Qu
Qu
Qu
p21
Figure 2: Effects of Qu on cell cycle. Qu is able to regulate cell cycle
by directly binding several molecular targets and, depending on the
cell type and tumor origin, it blocks the cell cycle at G2/M or at
the G1/S transition. At the G1/S transition, Qu blocks cell-cycle
progression through the up-regulation of p21 and p27 and p53.
p21 exerts an inhibitory activity on several CDKs. In particular, p21
inhibits CDK2-cyclin E, with the consequent inhibition of CDK2-
dependent phosphorylation of pRb and the sequestration of E2F1,
thus inhibiting gene transcription induced by E2F1 and progression
into and through S phase. p21 also inhibits CDK2-cyclin A and
CDK1-cyclin B, which are essential for progression through S phase
and G2, respectively. p27 exerts several effects on cell cycle, but only
under certain conditions it can inhibit the complexes CDK4-cyclin
D and CDK6-cyclin D. The tumor suppressor p53, once activated,
can induce several different cellular responses, including growth
arrest and apoptosis. Growth arrest is essentially elicited through
the up-regulation of the genes that encode for inhibitors of cell-cycle
progression, including p21 and p27. In different cellular models,
Qu stabilizes p53 both at mRNA and protein levels. Apart from
blocking cell growth through the direct action on key modulators of
cell cycle, Qu is able to induce apoptosis via mitochondrial pathway:
indeed, Qu can disrupt MMP, which in turn provokes the release
of cytochrome c in the cytoplasm, a phenomenon that activates
multiple caspases, such as caspase-3 and -7.
Qu exposure results in proteasomal degradation of survivin
[127], according to another proposed model, Qu treatment
raises cyclin B1 and p53 proteins that, in turn, increase
survivin and p21 protein expression, thereby inhibiting
apoptosis [126]. Third, Qu likely triggers apoptosis through
the generation of ROS and the subsequent activation of
AMPKα1 and ASK1 which is, in turn, accompanied by p38
activation and recruitment of caspases [63]. Fourth, the
antiproliferative and pro-apoptotic effects could be related
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to the capability of Qu to directly bind tubulin, provoking
the depolymerization of cellular microtubules [128]. Fifth,
Qu is a potent enhancer of TNF-related apoptosis-inducing
ligand (TRAIL)-induced apoptosis, through the induction
of the expression of death receptor (DR)-5, a phenomenon
that specifically occurs in prostate cancer cells [129]. The
up-regulation of DR5, together with the down-regulation
of c-FLIP (which is an inhibitor of caspase-8), are two
mechanisms involved in Qu-induced recovery of TRAIL
sensitivity, at least in hepatocellular carcinoma cells [130].
Of note, the enhancement of TRAIL-induced apoptosis by
Qu also occurs through the inhibition of the expression of
survivin in the ERK-MSK1 signal pathway [81].
Thus, the capability of Qu to induce apoptosis in
cancer cells (via both the intrinsic and extrinsic pathways)
undoubtedly renders this molecule an interesting tool in the
oncology field.
4.5. Qu Influences p53 Activity. Several studies have investi-
gated the role of p53 in the antiproliferative and proapoptotic
action of Qu on tumor cell lines. In HepG2 cells, Qu
causes cell-cycle arrest and apoptosis by inducing p53
phosphorylation and by stabilizing p53 both at the mRNA
and protein level [131]. In HCT116 colon carcinoma cells,
p53 contributes to Qu-mediated higher expression of NAG-
1, which in turn triggers apoptosis [132]. It is interesting to
note that the presence of p53 limits the effect of Qu, since
when p53 is inhibited, cells become more sensitive to Qu-
related cytotoxicity and Qu-related apoptosis. p53 elevates
the p21 level, which may attenuate the proapoptotic effects
of Qu in p53-wild-type tumor cells [126]. The H1299 lung
carcinoma cell line, which is a p53-null cell line, is more
susceptible to Qu-induced cytotoxicity than the A549 lung
carcinoma cell line, which expresses a wild-type form of
p53. In A549 cells, Qu-induced cytotoxicity and apoptosis
are augmented when an inhibitor of p53 or an antisense
oligonucleotide targeting p53 is used [126].
The effect of the presence or absence of p53 on Qu-
induced cytotoxicity and apoptosis is consistent with the
involvement of Qu in the oxidative cell balance. This is well
explained by a new model of the p53-dependent regulation
of intracellular ROS (Figure 3). p53 can have an antioxidant
function in unstressed or low-stressed cells through the
regulation of a series of genes related to such activity. Among
these genes, the most important are the microsomal GSH
transferase homolog PIG12 [133], aldehyde dehydrogenase
ALDH4A1 [134], Gpx1, Mn-superoxide dismutase SOD2
[135] and catalase [136]. Moreover, two members of the ses-
trin family, that is, SESN1 (pa26) and SESN2 (hi95), are also
regulated by p53 [137, 138]. Sestrins act as components of the
peroxiredoxin regeneration system in response to themassive
bursts of H2O2 occurring during signal transduction. In
unstressed cells, a good functionality of p53 is required for
reducing intracellular ROS levels [139]. When p53 functions
are blocked, or when its gene (TP53) is knocked out, a
significant increase of intracellular ROS can be observed.
ROS increase in p53-deficient cells is correlated with the
down-regulation of the p53-regulated genes GPX1, SESN1
and SESN2, suggesting that p53 is required for maintaining
these genes functional [139]. It is interesting to note that in a
model of mild or severe H2O2-induced stress, cells knocked
out by p53 exhibit much higher ROS levels than controls
[140, 141]. Furthermore, p53 deficiency sensitizes cells to
H2O2 damage, reducing viability and triggering apoptosis,
and causes an excessive oxidation of DNA after challenge
with H2O2 [140, 141].
4.6. Normal Cells Still Continue to Behave Normally. Despite
the fact that the effects of Qu have been analyzed in a
variety of cancer cells, little is known about its effects
on normal, non-transformed human cells. In general, the
most striking difference between normal and tumor cells
is that tumor cell lines are prone to cell-cycle arrest and
apoptosis at Qu concentrations that have no or little effect
on non-transformed cells [142]. For example, in human lung
embryonic fibroblasts and human umbilical vein endothelial
cells, Qu exerts cytotoxicity by increasing intracellular ROS
levels only when present at very high concentrations, that
is, from 100 to 500 μM [142]. Recently, we have shown
that treating human peripheral blood lymphocytes (PBL)
with Qu causes a loss of mitochondrial membrane potential
only in a small amount of cells, and that this effect occurs
only at high concentrations, that is, >100 μM [101]. In
activated or proliferating PBL, cell death seemed to be
independent from the entrance into the cell cycle of resting
lymphocytes (a phenomenon that typically occurs after
antigenic stimulation). In this model, Qu did not even
increase PBL susceptibility to CD95-induced apoptosis [101,
113]. It is important to note that the doses that were not
effective for PBL (i.e., <50 μM) were highly toxic for cancer
cells or tumor cell lines (Figure 4).
Indeed, the ability of Qu to exert antiproliferative and
proapoptotic effects on normal cells only at very high
concentrations sharply contrasts with the low concentrations
needed to exert the same effects on cancer cells that are, for
example, 3.5 μM for the B16-BL6 murine melanoma cell line
[143], 25 μM for PC-3 (p53-null cells) and DU-145 (p53-
mutated cells) human prostate cancer cell lines [116] and
10 μM for SK-Br3, MDA-MB-453 andMDA-MB-231 human
breast carcinoma cells [114]. Interestingly, the proliferation
of MCF-10A cells, which are normal breast epithelial cells,
is not affected by 10 μM of Qu [114] and, similarly, in the
normal fibroblast cell line BG-9 Qu does not affect cell
growth [116].
Qu protects mouse thymocytes from oxidative stress-
mediated apoptosis [144]. The antioxidant activity of Qu
was evaluated using the “G/GO system” in mouse normal
thymocyte cells, in which hydroxyl radicals are constantly
produced by glucose oxidase from glucose substrate. In this
model, Qu pretreatment significantly reduced the G/GO-
induced apoptosis of thymocytes and suppressed DNA-
binding activity of redox state-sensitive transcription factors,
such as NFkB, AP-1 and p53. The pretreatment of primary
rat hippocampal cultures with Qu significantly decreased
cytotoxicity and apoptosis induced by amyloid β-peptide
[145]. Similarly, the effect of a conditionedmedium obtained
from astrocytes treated with the proinflammatory cytokine
IL-1β and Qu has been evaluated on human neurons. In the
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presence of Qu, a significant decrease in neuronal apoptosis
has been observed, which is caused by the inhibition of
inflammatory mediators, including interleukin (IL)-6, IL-8
and monocyte chemoattractant protein 1, and the increase
in the expression of superoxide dismutase and thioredoxin
mediators [146].
In summary, what emerges from the few studies on
healthy cells is that the concentrations of Qu that can be
obtained with a diet rich in these flavonoids are capable of
exerting significant effects on tumor cells, while not affecting
cell cycle or cell activation of normal, non-transformed cells.
5. In Vivo Studies and Their Problems
5.1. Carcinogenesis in Different Animal Models. Although
different aspects of the molecular mechanisms involved in
the preventive effects of Qu on cancer have been covered,
its efficacy in vivo as chemopreventer or chemoterapeutical
has to be further elucidated. For this purpose, in recent years
the effects of Qu have been studied in several animal models
of carcinogenesis. Administration of Qu before the initiation
stage of carcinogenesis reduced benzo(a)pyrene-induced
lung tumor burden in mice which showed an increase in
the activity of antioxidant enzymes, including superoxide
dismutase, catalase, GSH peroxidase, GSH-S-transferase,
GSH reductase and a decrease in the levels of lipid peroxides
[147]. Similarly, administration of Qu supplements prior to
exposure of azoxymethane as carcinogen drastically reduced
the incidence of aberrant crypt foci and preneoplastic lesions
in rat colon [148]. Qu was tested as a possible treatment
for primary and invasive mammary carcinoma induced by
dimethyl-benz-(a)-anthracene [149]. A direct injection of
Qu into the tumor mass once a week for 4 weeks significantly
reduced the volume of the neoplastic lesions.
In a recent study, treatment with both N-nitroso-
diethylamine as cancer-inducer and Qu as preventer pro-
tected rats against hepatocarcinoma; this was accompa-
nied by the maintenance of a correct intracellular oxi-
dant/antioxidant status. In the presence of Qu, lipid perox-
idation was inhibited, and GSH and GSH peroxidase exerted
protective effects against oxidative damage [150]. When
administered by intraperitoneal injection to mice previously
engrafted with lung tumor cells, Qu had a growth-inhibitory
activity [143]. Other than a significant dose-dependent delay
in tumor growth, together with apigenin Qu displays a
potent anti-invasive activity on the highly metastatic B16-
BL6 melanoma cells in vitro [143]. Qu, in combination with
resveratrol and catechins, was able to reduce distal metastatic
invasions, especially to liver and bone, in nude mice through
the up-regulation of the forkhead box O1 (FOXO1) and
NFKBIA (IkappaBalpha) genes, which activate apoptosis and
inhibit NFκB activity [151].
5.2. The Problem of Solubility in Water and Possible Solutions.
The limited solubility of Qu in water presents a major
problem for its administration as a chemopreventer. Accord-
ingly, many studies analyzed possible complexes able to
transport Qu to various tissues [152, 153]. Promising studies
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Figure 4: Changes in cell viability, apoptosis and content of H2O2, O2
− and GSH in U937 tumor cell line treated for 24 h with
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−. Qu also causes a small change in the percentage of cells that do not bind the dye,
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have been obtained with polyethylene glycol (PEG) and sul-
fobutyl ether-7beta-cyclodextrin (SBE7betaCD) [154, 155].
The association of Qu to PEG (Q-PEGL) has been tested
in different mouse models through intravenous injections.
The biodistribution and the antitumor activity of Qu have
been evaluated in mice bearing lung cancer and in mice
bearing colon adenocarcinoma and hepatoma. Interestingly,
Q-PEGL has a better solubility in water, and prolongs the
circulation times of Qu in blood, enhancing its antitumor
activity [155].
The use of Qu bound to SBE7betaCD carrier has been
studied in the BDF1 mouse model of melanoma, after oral
administration of such compounds. Qu-SBE7betaCD com-
plex significantly improved anti-cancer activity of Qu, with
decreased density of the microvessel within the melanoma
[154].
Finally, another strategy to bypass the poor water-
solubility of Qu was the use of a vesiculated form of Qu in
galactosylated liposomes, able to bind galactosyl receptors
on the surface of hepatic cells. In rats, Qu-galactosylated
liposomes have been tested against diethyl nitrosamine
induced hepatocarcinoma: a decrease in the number of both
hyperplastic nodules and preneoplastic lesions in the rat liver
have been reported [156].
6. Relevance for Human Health
The capacity of Qu to act as a chemotherapeutical compound
is poorly studied, even if the combination of curcumin and
Qu appears to reduce the number and size of ileal and rectal
adenomas in patients with familial adenomatous polyposis,
without the onset of an appreciable toxicity [157]. It is to
note that all the epidemiological studies that often report
contrasting data, do not have the possibility to evaluate the
activity of Qu as such, but have to cope with the dietary
intake of this flavonoid.
Qu can be considered a very interesting candidate for
clinical applications in the prevention (or even in the treat-
ment) of some forms of cancer, as several data consistently
support its safety for human health and the lack of adverse
effects, at least at the levels of the estimated dietary intake
[158]. With particular regard to dietary supplementation,
apparently controversial effects have been observed in vitro
and in vivo. Indeed, although in vitro studies demonstrated
the existence of a Qu-related mutagenicity, long-term in vivo
toxicity studies failed to show any Qu-related promotion of
carcinogenicity after oral administration.
Twomechanisms have been proposed to explain this dual
aspect. First, Qu scarce absorption, together with almost
complete metabolism in the intestinal tract, support the
importance of Qu degradation for the elimination of its
toxicity [159]. As a result of the first-pass effect, oral admin-
istration of Qu causes its almost complete metabolization,
and metabolites still retain antioxidant properties [160].
Conversely, severe toxic effects can be exerted when Qu
is administered intraperitoneally [161]. Second, multiple
detoxifying mechanisms exist, in vivo, to limit the pro-
oxidant effects of Qu. As far as human clinical trials are
concerned, no significant adverse effects were reported after
oral administration of Qu at doses up to 1000mg day−1,
corresponding to a high daily supplementation, for up to 12
weeks. Only one old study reported the presence of urinary
bladder and intestinal tumors in rats fed with a dietary
supplement of Qu of the order of 50mg kg−1 body weight per
day [162]. However, these results were not confirmed by any
other long-term study performed with several-fold higher
doses of Qu [163, 164], and in fact the occurrence of the
aforementioned cancers was ascribed to the potential cross-
contamination of the bracken fern diet with the carcinogen
ptaquiloside [165].
Parallel to safety studies, exhaustive studies on efficacy of
Qu in human beings are also needed. The sole clinical study
performed with Qu has determined the serum concentration
of a water-soluble pro-drug form of Qu, named QC12, after
oral or intravenous administration to patients with different
types of tumor, but did not evaluate any clinical effect [166].
It would be of extreme interest to expand this observation,
and plan studies on different types of patients, ranging from
those with treatable forms of cancer, to those who have failed
any form of chemo- or radiotherapy.
At present, single natural chemicals are investigated in
clinical trials to evaluate their potential chemopreventive
activity on different types of cancer. For instance, lycopene
and genistein are investigated for the prevention of prostate
cancer, resveratrol and curcumin particularly for colon
cancer, while green tea preferentially for solid tumors, lung
and esophageal cancers [93]. The inclusion of Qu in this
group will likely expand the possibility to fight against this
or other types of human diseases. Finally, it is to note
that the use of Qu is likely to be much higher than what
we imagine, as it is freely sold almost everywhere, and
easily available as dietary supplement (e.g., in the General
Nutrition Corporation—GNC stores).
7. Conclusions
The studies of Qu on cellular models offer an almost
exhaustive explanation of themechanisms that link Qu to the
oxidative cell balance and to the control of cell-cycle phases.
Promising results have been obtained in the evaluation of
the biological effects of Qu on both cancer and normal
cells: the high toxicity of Qu for cancer cells, along with
the characteristic to exert antiproliferative and proapoptotic
effects on normal cells only at high concentrations are crucial
aspects in the field of anticancer research, whose important
goal is the identification of drugs that selectively kill tumor
cells without damaging normal cells.
Results from cellular models invite major attention to
study Qu in more complex and sophisticated animal models,
such as those represented by animals with genetic defects in
one or more genes that control oncogenesis, or with primary
or secondary immune deficiencies. Furthermore, controlled
clinical trials are needed to assess both the chemopreventive
and chemoterapeutic effects of this molecule in a pure form.
For this reason, investigations focused on pharmacokinetic
and bioavailability in different regions of the organism are
urgently needed.
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